

IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (canceled)
2. (original) A method of treating or preventing HCV infection in a mammalian subject comprising administration to that subject of a therapeutically effective amount of a PPAR α agonist.
3. (original) The method according to Claim 2 wherein the PPAR α agonist is administered in combination with one or more therapeutic agents selected from interferon- α , pegylated interferon- α , ribavirin, a HCV NS3 protease inhibitor, a HCV polymerase inhibitor, anti-HCV antibodies and a HCV vaccine.
4. (currently amended) The ~~use according to Claim 1 or the~~ method according to Claim 2 ~~or 3~~ wherein the mammal is a human.
5. (original) A method of inhibiting entry of HCV to a cell comprising contacting said cell with a PPAR α agonist.
6. (original) The method according to Claim 5 wherein the cell is a hepatocyte.
7. (original) A pharmaceutical composition comprising a PPAR α agonist and a pharmaceutically acceptable carrier in combination with one or more therapeutic agents selected from interferon- α , pegylated interferon- α , ribavirin, a HCV NS3 protease inhibitor, a HCV polymerase inhibitor, anti-HCV antibodies and a HCV vaccine.
8. (original) A kit comprising a PPAR α agonist and one or more therapeutic agents selected from interferon- α , pegylated interferon- α , ribavirin, a HCV NS3 protease inhibitor, a HCV polymerase inhibitor, anti-HCV antibodies and a HCV vaccine, for simultaneous or sequential administration.
9. (currently amended) The ~~use according to Claim 1 or 4, the~~ method according to Claim 2 ~~any one of Claims 2 to 6, the pharmaceutical composition according to~~

~~Claim 7, or the kit according to Claim 8~~ wherein the PPAR α agonist is a selective PPAR α agonist.

10. (currently amended) ~~The use according to Claim 1 or 4, the method according to Claim 2 any one of Claims 2 to 6, the pharmaceutical composition according to Claim 7, or the kit according to Claim 8~~ wherein the PPAR α agonist is a PPAR α/γ dual agonist.

11. (currently amended) ~~The use according to Claim 1 or 4, the method according to Claim 2 any one of Claims 2 to 6, the pharmaceutical composition according to Claim 7, or the kit according to Claim 8~~ wherein the PPAR α agonist is fenofibrate, bezafibrate, ciprofibrate, gemfibrozil or MK-0767.

12. (new) The method according to Claim 3, wherein the mammal is a human.

13. (new) The method according to Claim 5 wherein the PPAR α agonist is a selective PPAR α agonist.

14. (new) The method according to Claim 5 wherein the PPAR α agonist is PPAR α/γ dual agonist.

15. (new) The method according to Claim 5 wherein the PPAR α agonist is fenofibrate, bezafibrate, ciprofibrate, gemfibrozil or MK-0767.

16. (new) The pharmaceutical composition according to Claim 7 wherein the PPAR α agonist is a selective PPAR α agonist.

17. (new) The pharmaceutical composition according to Claim 7 wherein the PPAR α agonist is PPAR α/γ dual agonist.

18. (new) The pharmaceutical composition according to Claim 7 wherein the PPAR α agonist is fenofibrate, bezafibrate, ciprofibrate, gemfibrozil or MK-0767.

19. (new) The kit according to Claim 8 wherein the PPAR α agonist is a selective PPAR α agonist.

20. (new) The kit according to Claim 8 wherein the PPAR α agonist is PPAR α/γ dual agonist.

21. (new) The kit according to Claim 8 wherein the PPAR α agonist is fenofibrate, bezafibrate, ciprofibrate, gemfibrozil or MK-0767.